AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

In the Destiny Breast-09 study, AstraZeneca tested Enhertu plus Perjeta in patients with an advanced form of breast cancer. Perjeta is a common breast cancer treatment.

AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor- positive, HER2-low or HER2-ultralow ...

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic breast cancer. Read more here.

Enhertu reduced the risk of disease progression or death by 36%, with a median PFS of 13.2 months versus 8.1 months for chemotherapy. The trial showed an ORR of 62.6% for Enhertu compared to 34.4% ...

ENHERTU is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Wirestock. AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients.Enhertu was approved for the ...

AstraZeneca is jointly developing and commercializing ENHERTU, which is the drug being evaluated in the DESTINY-Endometrial01 phase 3 trial, with Daiichi Sankyo under a global collaboration.

AstraZeneca Plc AZN on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care THP (a ...

Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting ENHERTU is a specifically ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...